In a biotech landscape dominated by billion-dollar IPOs and sprawling R&D campuses, Xenikos operates from the fringes—just 2 employees, $300k in revenue, and a singular, audacious mission: resetting the human immune system. Their weapon of choice? T-Guard™, a dual-antibody therapy that loads toxins directly into T-cells. It’s a high-stakes gamble on precision medicine, executed with the leanest of resources.

"Xenikos isn't building a platform—they're building a single, lethal precision strike against dysregulated T-cells."

• Dual-antibody approach (CD3/CD7) for enhanced specificity
• Toxin-loaded design for direct T-cell elimination
• Focus on acute graft-versus-host disease (aGVHD) and other T-cell malignancies
• Ultra-lean operational model with minimal overhead

The traffic data tells a story of a company flying under the radar. With only 491 monthly visits, Xenikos isn't chasing broad audiences. The top search term—'maarten frijlink'—suggests their visibility is driven by key personnel or niche academic interest, not commercial marketing. This aligns with their profile: a pre-commercial biotech engaging directly with clinicians and researchers rather than consumers. The 'undefined' country traffic (68.2%) hints at either anonymized analytics or a global, scattered audience of specialists.